A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/711 (2006.01) A61K 47/24 (2006.01) A61P 35/00 (2006.01) A61P 35/02 (2006.01) A61K 9/127 (2006.01)
Patent
CA 2259144
The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crk1 nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.
L'invention concerne un nouveau type de compositions et de procédés pour le traitement du cancer, en particulier la leucémie myéloïde chronique (LMC). Les compositions renferment des oligonucléotides antisens pour hybridation sur acide nucléique Grb2 et Crkl, avec interaction des produits géniques résultants et de la protéine tumorigène bcr-abl. Séparément ou combiné entre elles, et même utilisées en association avec des oligonucléotides antisens ciblés sur les acides nucléiques bcr-abl, les compositions inhibent la prolifération des cellules cancéreuses de LMC.
Arlinghaus Ralph B.
Lopez-Berestein Gabriel
Tari Ana M.
Board Of Regents The University Of Texas System
Deeth Williams Wall Llp
LandOfFree
Inhibition of chronic myelogenous leukemic cell growth by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of chronic myelogenous leukemic cell growth by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of chronic myelogenous leukemic cell growth by... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1621565